|国家科技期刊平台
| 注册
首页|期刊导航|肿瘤学与转化医学（英文）|Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer

Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer

Heng Cao Yonggui Hong Kai Liang Peng Liu Jing Wang Yuanyuan Ji Lujuan Xu Weilong Wu Shengnan Guo Xuekun Song

肿瘤学与转化医学（英文）2020，Vol.6Issue(1)：10-15,6.
✕
肿瘤学与转化医学（英文）2020，Vol.6Issue(1)：10-15,6.DOI:10.1007/s10330-019-0370-0

Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer

Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer

Heng Cao 1Yonggui Hong 1Kai Liang 2Peng Liu 2Jing Wang 1Yuanyuan Ji 1Lujuan Xu 1Weilong Wu 1Shengnan Guo 1Xuekun Song3

作者信息

  • 1. Department of Oncology,Anyang Tumor Hospital,The Fourth Affiliated Hospital of Henan University of Science and Technology,Anyang 455000,China
  • 2. Department of Surgical Oncology,Anyang Tumor Hospital,The Fourth Affiliated Hospital of Henan University of Science and Technology,Anyang 455000,China
  • 3. Henan University of Chinese Medicine,Zhengzhou 450000,China
  • 折叠

摘要

关键词

non-small cell lung cancer(NSCLC)/anlotinib/tegafur gimerac/advanced stage

Key words

non-small cell lung cancer(NSCLC)/anlotinib/tegafur gimerac/advanced stage

引用本文复制引用

Heng Cao,Yonggui Hong,Kai Liang,Peng Liu,Jing Wang,Yuanyuan Ji,Lujuan Xu,Weilong Wu,Shengnan Guo,Xuekun Song..Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-small cell lung cancer[J].肿瘤学与转化医学（英文）,2020,6(1):10-15,6.

基金项目

Supported by a grant from the Youth National Science Foundation of China(No.61702164). （No.61702164）

肿瘤学与转化医学（英文）

OACSTPCD

2095-9621

访问量0
|
下载量0
段落导航相关论文